Update shared on10 Aug 2025
Fair value Increased 6.28%Ascendis Pharma's consensus price target has been raised to $250.41, driven by strong commercial momentum for Yorvipath, positive pipeline developments—particularly in rare diseases—and compelling interim COACH trial data in achondroplasia, reinforcing analyst confidence in both near-term execution and long-term upside.
Analyst Commentary
- Bullish analysts highlight strong commercial momentum and uptake for Yorvipath in hypoparathyroidism.
- Multiple analysts see significant upside from the TransCon pipeline, with compelling opportunities especially in rare diseases.
- Positive interim Phase 2 COACH trial results in achondroplasia children support improved efficacy of the combination therapy (QW TransCon CNP + QW TransCon hGH) relative to monotherapy and position Ascendis to capture greater market share.
- Upcoming 52-week COACH data in Q4 and the initiation of a Phase 3 combo trial are anticipated to further validate and optimize Ascendis’ clinical strategy.
- The differentiated efficacy profile and convenience of once-weekly dosing are viewed as key competitive advantages, supporting bullish upward price target revisions.
What's in the News
- FDA approved SKYTROFA (TransCon hGH) for adult growth hormone deficiency, expanding its current pediatric indication, following positive Phase 3 foresiGHt trial results.
- Long-term Phase 3 PaTHway and Phase 2 PaTH Forward trial data showed TransCon PTH delivered sustained efficacy, safety, and improved quality of life for adults with hypoparathyroidism, with no new safety concerns and maintained renal function.
- Week 52 ApproaCH Trial in pediatric achondroplasia demonstrated TransCon CNP significantly improved growth velocity and bone morphometry over placebo, with favorable safety and tolerability; new interim results support these findings.
- FDA accepted TransCon CNP for priority review as a treatment for children with achondroplasia (PDUFA target in late November), without plans for an advisory committee meeting.
- Interim COACH Trial data in pediatric achondroplasia showed combination TransCon CNP and TransCon hGH led to significant growth and proportionality improvements after 26 weeks, with safety profiles consistent with monotherapy.
Valuation Changes
Summary of Valuation Changes for Ascendis Pharma
- The Consensus Analyst Price Target has risen from $235.29 to $250.41.
- The Consensus Revenue Growth forecasts for Ascendis Pharma has significantly fallen from 73.5% per annum to 62.9% per annum.
- The Net Profit Margin for Ascendis Pharma has significantly risen from 36.15% to 41.33%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.